Learn More
PURPOSE Evaluate conversion rate of patients with unresectable colorectal-liver metastasis to complete resection with hepatic-arterial infusion plus systemic chemotherapy including bevacizumab (Bev).(More)
e11045 Background: The prognosis of BCLM is poor with a median survival of < 6 months (mths). There is data for improved survival in pts with colorectal liver metastases treated with HAI floxuridine(More)
PURPOSE Add systemic bevacizumab (Bev) to adjuvant hepatic arterial infusion (HAI) plus systemic therapy after liver resection to increase recurrence-free survival (RFS). PATIENTS AND METHODS(More)
BACKGROUND The prognostic and predictive abilities of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) coupled with conventional computed tomography (CT) have not been studied in(More)